Evaluation of response to gemcitabine plus cisplatin-based chemotherapy using positron emission computed tomography for metastatic bladder cancer

Table 3 Treatment recommendations in metastatic baldder carcinoma

First line treatment			Second and third line treatments
Patients eligible to cisplatin	Unfit patients	Cisplatin sensitive disease	Cisplatin refractory disease
MVAC, HD-MVAC, GC, and DD-GC	GCa and MCAVI	Cisplatin based doublet not used in first line	Vinflunine, Paclitaxel-gemcitabine, and all actives drugs not used

MVAC: Methotrexate-vinblastine-doxorubicin-cisplatin; HD: High dose; GC: Gemcitabin-cisplatin; DD: Dose dense; MCAVI: Methotrexate-carboplatin-vinblastine; GCa: Gemcitabine plus carboplatin;